Jonathan King, MD
Medical Oncology · Grand Junction, CONPI 1356506265
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,880 of the $3,717 with a category attached, or 77.5%. Pfizer accounts for 78.8% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $3,407, more than ten times the $16 reported in 2020.
Across 29 payments — averaging $128.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Medtronic$123
- Beone Medicines USA, Inc.$121
- Novartis$119
- AbbVie$105
- Seagen Inc.$76
- plus $245 from 8 others
Across 40 payments — averaging $11,596 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$264K
- Janssen Research & Development, LLC$114K
- Amgen$54K
- Eli Lilly$31K
What the payments were for
- Consulting fees$2,88077%
- Food & beverage$81622%
- Education$211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 4 | $2,928 |
| Medtronic | 1 | $123 |
| Beone Medicines USA, Inc. | 1 | $121 |
| Novartis | 6 | $119 |
| AbbVie | 4 | $105 |
| Seagen Inc. | 1 | $76 |
| E.r. Squibb & Sons, L.L.C. | 2 | $57 |
| AstraZeneca | 3 | $55 |
| Amgen(2 entities) | 2 | $33 |
| GSK | 1 | $26 |
| Fresenius Kabi USA, LLC | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,717 in reported general payments places this provider in the 65th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AyvakitAvapritinib | 12 | $472,910 |
| RevlimidLenalidomide | 28 | $448,168 |
| PomalystPomalidomide | 19 | $435,051 |
| NubeqaDarolutamide | 31 | $431,804 |
| JakafiRuxolitinib Phosphate | 22 | $357,210 |
| ImbruvicaIbrutinib | 20 | $326,172 |
| ErleadaApalutamide | 16 | $226,603 |
| SprycelDasatinib | 15 | $214,074 |
| CalquenceAcalabrutinib Maleate | 13 | $200,810 |
| XtandiEnzalutamide | 13 | $181,462 |
| Lenalidomide | 11 | $164,563 |
| OrgovyxRelugolix | 36 | $96,212 |
| CreonLipase/Protease/Amylase | 20 | $95,995 |
| Abiraterone Acetate | 71 | $84,141 |
| XareltoRivaroxaban | 23 | $27,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $57 | $649,12434 claims |
| AstraZenecaCalquence | $55 | $200,81013 claims |
| AbbVieCreon | $105 | $95,99520 claims |
| PfizerEliquis | $2,928 | $12,23923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 96 medical oncology providers in Colorado.
Other medical oncology in Grand Junction
- Allan MillerGrand Junction$1K
- Kristina GoutsouliakGrand Junction$1K
- David CamidgeAurora$648K
- Paul BunnAurora$354K
- Chelsea GawryletzFort Collins$301K
- Sapna PatelAurora$186K
- Sunnie KimAurora$81K
- Virginia BorgesAurora$68K
- Erin SchenkAurora$63K
- Karl LewisAurora$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.